Sales of ABILIFY® (aripiprazole) Tablets 1, for
schizophrenia (approval was received from the FDA in November 2002) and
acute manic and mixed episodes associated with Bipolar I Disorder
(approval was received from the FDA in September 2004), exceeded U.S. $1
billion within its first four years on the market.
Sales of PLETAL® (cilostazol) Tablets 2,
the Otsuka-developed treatment for intermittent claudication approved by
the FDA in January 1999, increased the company's revenues significantly
since the product was launched. Annual revenues nearly quadrupled over
the period 1999 to 2000 and more than doubled in 2001. Sales of PLETAL
in 2002, 2003 and 2004 continued a dramatic growth trend. In addition, Otsuka
has a co-promotion agreement with
Santarus, Inc. for the sale of
ZEGERID® (omeprazole/sodium
bicarbonate) 3
which received NDA approval in June 2004.
OAPI's product
portfolio is focused primarily in the areas of cardiovascular,
neuroscience and gastrointestinal areas. In order to meet the needs of
the physicians and other healthcare professionals within these areas,
OAPI has hired and trained specialty sales forces for each. If you are
an experienced medical representative with knowledge in these areas, and
are interested in career opportunities with OAPI's cardiovascular,
neuroscience or gastrointestinal specialty sales forces, please visit
the "Careers" section on this Web Site to view positions which are
currently available.
1 Please see FULL PRODUCT INFORMATION including for ABILIFY.
2 Please see FULL PRODUCT INFORMATION including for PLETAL.
3 Please see FULL PRODUCT INFORMATION for ZEGERID.
|
